html
html
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="description" content="Explore the history and cultural impact of MDMA (Ecstasy), from its synthesis to its influence on modern society.">
<meta name="keywords" content="MDMA, Ecstasy, history, synthesis, Merck, Alexander Shulgin, culture, psychiatry, therapeutic">
<meta name="author" content="Konan">
<title>A Short History of Ecstasy (MDMA)</title>
<link rel="icon" type="image/x-icon" href="favicon.ico">
<link href="https://fonts.googleapis.com/css2?family=Orbitron:wght@400;700&family=Roboto:wght@400;700&family=Exo+2&family=Unica+One&family=Tangerine&family=VT323&family=Roboto+Slab:wght@400;700&display=swap" rel="stylesheet">
<link rel="stylesheet" href="styles.css">
<script src="script.js" defer></script>
</head>
<body>
<header>
<h1>A Short History of Ecstasy (MDMA)</h1>
</header>
<main>
<section id="timeline">
<h2>Timeline of MDMA</h2>
<h5>Click the timeline events for more information:</h5>
<div class="event" onclick="showDetails('e1912')">
<!-- Test Tube Icon -->
<svg class="event-icon" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="24" height="24">
<path d="M6 2v2h1v15.5c0 1.93 1.57 3.5 3.5 3.5s3.5-1.57 3.5-3.5V4h1V2H6zm7 2v15.5c0 1.38-1.12 2.5-2.5 2.5S8 20.88 8 19.5V4h5z"/>
Enter to Rename, Shift+Enter to Preview
css
css
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
body {
font-family: 'Roboto', sans-serif;
margin: 0;
padding: 0;
background-color: #e6f7ff;
color: #222;
}
header {
background-color: #222;
color: white;
text-align: center;
padding: 1.5em;
font-family: 'Orbitron', sans-serif;
}
h2 {
position: relative;
text-align: center;
color: #f1f2f3;
background-color: #232324;
border-radius: 12.5px;
font-size: 2.055em;
font-family: 'Unica One', serif;
}
h5 {
position: relative;
Enter to Rename, Shift+Enter to Preview
js
js
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
if (typeof document === 'undefined') {
global.document = {
addEventListener: (event, callback) => {
if (event === 'DOMContentLoaded') {
callback();
}
},
getElementById: (id) => ({
textContent: '',
set textContent(value) {
console.log(`Setting textContent of #${id} to: ${value}`);
}
})
};
global.window = global;
}
// Wait until fully loaded
window.addEventListener('load', function () {
// Event-Details mit erweiterten Informationen
const eventDetails = {
e1912: "In 1912, MDMA (3,4-Methylenedioxy-methamphetamine) was first synthesized by the German pharmaceutical company Merck. It was originally created as an intermediate compound for the synthesis of other substances. At this stage, the psychoactive effects of MDMA were not known, and the compound was not considered for human consumption. Merck never pursued MDMA's further development.",
e1927: "In 1927, pharmacological testing on MDMA-like substances was revisited, although the psychoactive effects of MDMA were still not explored. The compound remained largely overlooked in the context of psychoactive research at the time. It was still only considered a byproduct of synthetic chemistry and was not associated with any specific application in the medical field.",
e1950: "In the 1950s, the U.S. Army conducted research on compounds similar to MDMA as part of its interest in psychological warfare and mind-altering substances. While MDMA itself was not a primary focus, its related compounds were investigated for potential use in military operations, specifically for their effects on human perception and behavior. These studies helped pave the way for later interest in MDMA's psychological effects.",
e1978: "In 1978, chemist Alexander Shulgin first reported on the psychoactive effects of MDMA, marking a pivotal moment in the compound's history. Shulgin, who had synthesized MDMA for the first time in the early 1970s, conducted experiments with the substance and explored its effects on consciousness. This led to an increased interest in MDMA as a potential tool for psychotherapy, particularly in the context of enhancing emotional openness and communication during therapeutic sessions.",
e1990: "In the 1990s, MDMA became central to global club and rave culture. It was widely used as a recreational drug, known for its stimulant and empathogenic effects, and was frequently associated with dance and electronic music scenes. As MDMA's popularity grew, concerns about its safety and regulation intensified. In response to growing use, the U.S. government classified MDMA as a Schedule I controlled substance in 1985, significantly restricting its availability for both research and recreational use.",
e2000: "In the early 2000s, MDMA's popularity continued to soar within underground party scenes, with its use spreading to a broader range of social groups. Although illegal in most countries, the drug was still widely available on the black market. During this period, there was an increased focus on the potential therapeutic uses of MDMA, with some researchers advocating for its use in the treatment of post-traumatic stress disorder (PTSD) and other mental health conditions.",
e2010: "In the 2010s, MDMA began to be explored more seriously in scientific research, particularly in the context of psychotherapy. Researchers, including those at the Multidisciplinary Association for Psychedelic Studies (MAPS), conducted clinical trials to assess MDMA’s potential as a treatment for PTSD and other psychiatric disorders. This decade saw the beginning of a shift towards the medicalization of MDMA, leading to a reevaluation of its legal status in various countries.",
Enter to Rename, Shift+Enter to Preview
BROWSER
Console
Run